Those effects were linked to increased levels of IGF-1 receptor, insulin receptor substrate-1 (IRS-1) and -4 (IRS-4) and glial fibrillary acidic protein (GFAP), a marker of astroglial activation and astrocytosis, two AD-related conditions [4]. Here, GFAP is linked to Alzheimer disease.